Showing 6441-6450 of 7113 results for "".
- Doctors Welcome VOLBELLA XC for Lipshttps://practicaldermatology.com/news/doctors-welcome-volbella-xc-for-lips/2458401/Allergan’s JUVÉDERM VOLBELLA XC is here. The newly approved filler is now available for lip augmentation and correction of perioral rhytids in adults over the age of 21. Physicians can purchase VOLBELLA XC after completion of an
- Sweden Greenlights Allergan's Double Chin-Melting BELKYRA®https://practicaldermatology.com/news/sweden-greenlights-allergans-double-chin-melting-belkyra/2458404/The Swedish Medical Products Agency has greenlighted Allergan’s BELKYRA® (deoxycholic acid) for submental fat reduction. BELKYRA® is already licensed in Canada, Australia, Iceland, Hungary, Austria, Lithuania, Estonia, Latvia, Romania, Bulgaria and Norway, as well
- Allergan's New #ActuallySheCan Campaign Aims to Inspire Young Womenhttps://practicaldermatology.com/news/allergans-new-actuallyshecan-campaign-aims-to-inspire-young-women/2458407/Allergan’s new female empowerment campaign ActuallySheCanSM provides young women with inspirational advice and stresses the importance of female mentorship. The campaign includes portraits of actress Chloë Grace Mor
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study,
- Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketinghttps://practicaldermatology.com/news/aesthetics-industry-veteran-pat-altavilla-joins-suneva-medical-as-vice-president-of-marketing/2458410/Suneva Medical, Inc., appointed Pat Altavilla as vice president of marketing. With more than 30 years of experience in the aesthetics and medical fields, Altavilla will oversee all marketing aspects for the company, further fortifying the brand's strong le
- At-Home Nail Fungus Treatment Now Available From iSkinProductshttps://practicaldermatology.com/news/at-home-nail-fungus-treatment-now-available-from-iskinproducts/2458415/Cure-Ex nail fungus laser treatment device is now available from online beauty retailer, iSkinProducts. The portable device can be used on fingernails or toenails and a user can use the Cure-Ex laser from the comfort of their own home, according to the company. The Cure-Ex nail fungus tre
- DermTech Announces Validation Study Publicationhttps://practicaldermatology.com/news/dermtech-announces-validation-study-publication/2458414/DermTech, Inc., an emerging diagnostics company focusing on non-invasive gene expression tests for skin cancer and inflammatory diseases, recently published "Development and Validation of a Non-Invasive 2-Gene Molecular Assay for Cutaneous Melanoma", in the Journal of the American A
- Valeant Appoints New Chief Quality Officerhttps://practicaldermatology.com/news/valeant-appoints-new-chief-quality-officer/2458416/Valeant Pharmaceuticals International, Inc. appointed Louis W. Yu, PhD to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016. Dr. Yu reports to Joseph C. Papa, C
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Ac